Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront and up to $650 million in milestone payments
07:42am, Wednesday, 22'nd May 2024
Biogen Inc. BIIB, -1.68% said Wednesday it's acquiring privately held Human Immunology Biosciences for $1.15 billion upfront and up to $650 million in potential milestone payments in a move aimed at b
Biogen to buy Human Immunology Biosciences in up to $1.8 bln deal
07:38am, Wednesday, 22'nd May 2024
Biogen said on Wednesday it had agreed to buy privately held Human Immunology Biosciences for $1.15 billion in upfront and up to $650 million in potential milestone payments.
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
07:30am, Wednesday, 22'nd May 2024
CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnolog
Why Biogen Inc. (BIIB) is a Top Momentum Stock for the Long-Term
10:51am, Tuesday, 21'st May 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Meridian Wealth Management LLC Cuts Stake in Biogen Inc. (NASDAQ:BIIB)
07:26am, Monday, 20'th May 2024
Meridian Wealth Management LLC decreased its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 79.2% during the fourth quarter, according to its most recent filing with the SEC. T
Biogen and Ionis Pharma shares slide as they end development of ALS treatment
02:07pm, Thursday, 16'th May 2024
The stocks of Biogen Inc. and Ionis Pharmaceuticals Inc. were lower Thursday, after the partners said they were terminating development of a treatment for the fatal disease Amyotrophic Lateral Scleros
Biogen, Ionis to discontinue development of ALS drug
07:41am, Thursday, 16'th May 2024
Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patie
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
07:30am, Thursday, 16'th May 2024
CAMBRIDGE, Mass. and CARLSBAD, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced the decision to terminate development of BII
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
07:30am, Thursday, 16'th May 2024
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis cont
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
01:15pm, Wednesday, 15'th May 2024
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's di
TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Mass
3 S&P 500 Stocks to Rival Nvidia's 2023 Performance in the Second Half of 2024
08:00am, Saturday, 11'th May 2024
The extraordinary performance of Nvidia (NASDAQ: NVDA ) in 2023 coincided with a seismic generative-AI rally that carried the entirety of the S&P 500 higher in a year that was punctuated by Fed intere
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
06:30am, Thursday, 09'th May 2024
Here's a question for you: What determines the value of a drug? Is it the number of lives it saves or how much it costs to make?
Biogen Reports Progress on Corporate Responsibility Priorities
07:30am, Thursday, 02'nd May 2024
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced publication of its 2023 Corporate Responsibility Report detailing progress on the company's commitment to
7 Retirement Stocks to Buy at a 52-Week Low in April
10:03am, Monday, 29'th Apr 2024
One of the best ways to keep your portfolio safe while generating consistent income is in safe, dividend-paying retirement stocks at 52-week lows. It's even better if you're buying into a reputable co
